Only some study participants have access to the tablet that can cut the risk of HIV infection by more than 90%.
Jane Mahlangu is set to become one of the first 100 people in South Africa to receive an experimental jab that could prevent HIV - and make history
If it works, the world's latest HIV vaccine candidate may make it to market quicker than we think - and become a routine childhood vaccination
Recently the first participants in the HVTN 702 study received jabs of a vaccine that could stop HIV in its tracks
One tiny protein may hold the secret to ending the HIV pandemic.